Bonipar for Musculoskeletal Pain
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new herbal extract topical solution called Bonipar to determine if it works as well and as quickly as the commonly used diclofenac sodium topical solution for treating acute and chronic musculoskeletal pain. The researchers aim to assess whether Bonipar can serve as a reliable alternative for managing pain in muscles and joints. It targets individuals who frequently experience muscle or joint pain not well-controlled by their current treatment. Participants should not have used any topical agents on the affected area in the past three days and should not have certain health conditions, such as uncontrolled diabetes or active skin diseases. As a Phase 2 trial, this research focuses on measuring Bonipar's effectiveness in an initial, smaller group of people, offering participants a chance to explore a potentially effective new treatment option.
Do I need to stop my current medications to join the trial?
The trial does not specify if you need to stop your current medications, but it mentions that patients taking opioids or NSAIDs for their pain can participate if their pain is not well-controlled. You should discuss your specific medications with the study team.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Previous studies have found that Bonipar has fewer side effects than diclofenac for relieving muscle and joint pain. Users of Bonipar reported fewer unwanted effects, suggesting it is a well-tolerated option for managing pain.
Diclofenac, widely used since 1974, is generally considered safe but can cause skin reactions, such as contact dermatitis, in a small number of users. This irritation may include redness or swelling. Despite this, diclofenac is often compared to aspirin in terms of safety and is usually well-tolerated by most people.
Overall, both treatments have shown relative safety, with Bonipar having a slight advantage in terms of fewer side effects.12345Why do researchers think this study treatment might be promising?
Unlike the standard treatments for acute and chronic musculoskeletal pain, Bonipar is an experimental option that researchers are excited about due to its unique mechanism of action. While most current treatments focus on reducing inflammation or numbing pain, Bonipar is designed to target the pain at a cellular level, potentially offering more effective relief with fewer side effects. This approach could lead to faster and longer-lasting pain management for patients.
What evidence suggests that this trial's treatments could be effective?
Research has shown that Bonipar, one of the treatments in this trial, may significantly reduce pain in individuals with both short-term and long-term muscle and joint issues. One study found that patients experienced 50% less pain after just one week of using Bonipar, suggesting it might quickly aid in pain relief.
Diclofenac sodium topical solution 1.5%, another treatment option in this trial, is well-known for easing pain and improving movement, particularly for knee arthritis. Research has found it can be as effective as diclofenac pills. This trial will compare Bonipar to the trusted diclofenac solution to determine if Bonipar provides similar relief.14567Who Is on the Research Team?
Lance Roy, MD
Principal Investigator
Duke University
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either Bonipar or diclofenac topical solution 1.5% for pain relief
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Bonipar
- Diclofenac sodium topical solution 1.5%
Find a Clinic Near You
Who Is Running the Clinical Trial?
Winston Parris, MD
Lead Sponsor